Postoperative outcomes and role of adjuvant therapy in common bile duct cancer
- 19 December 2025
- journal article
- abstracts
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 12,p. 69-79
Abstract
Objective. To determine prognostic factors in resectable common bile duct (CBD) cancer and feasibility of adjuvant therapy. Material and methods. We retrospectively studied the results of pancreatoduodenectomy for CBD cancer in 1999—2023. Results. There were 89 patients, mortality rate was 5.6% (n=5), complications developed in 66 patients (74.2%), complications ≥ grade III — in 37 (41.7%) cases. Postoperative pancreatic fistula (POPF) grade B/C was detected in 29 (32.6%) cases. Postoperative chemotherapy was administered to 43 patients (gemcitabine-based therapy — 27, capecitabine alone — 15, capecitabine/oxaliplatin combination — 1). The median overall survival was 33 months, disease-free survival — 19 months. Among patients selected for assessment of long-term results (n=79), the median OS was 37 months, DFS — 30 months. Retroperitoneal invasion (RPI), pancreatic invasion (PI), perineural invasion (PNI), moderate/poor differentiation, R1 resection, retroperitoneal lymph node (LN) involvement worsened long-term results in multivariate analysis, regional LN involvement and elevated CA 19-9 — in univariate analysis. Accumulation of factors worsened prognosis. Postoperative chemotherapy improved OS (median OS 35 months vs. 16.5, p=0.035) in patients with two or more negative prognostic factors. Chemotherapy mode did not affect prognosis. Conclusion. Retroperitoneal, pancreatic and perineural invasion, R1 resection, moderate/poor tumor differentiation, lymph node involvement and elevated CA 19-9 are negative prognostic factors in CBD cancer. Postoperative capecitabine monotherapy is justified in patients with two or more negative factors.Keywords
This publication has 26 references indexed in Scilit:
- Vascular resection for distal cholangiocarcinomaSurgery Today, 2022
- Spread of lymph node metastasis and adjuvant therapy for distal cholangiocarcinomaInternational Journal of Clinical Oncology, 2022
- The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinomaThe American Journal of Surgery, 2019
- Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched AnalysisJournal of Gastrointestinal Surgery, 2018
- Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancerBritish Journal of Surgery, 2018
- Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinomaBritish Journal of Surgery, 2017
- Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analysis of prognostic factorsAsian Journal of Surgery, 2017
- Recurrence after resection with curative intent for distal cholangiocarcinomaBritish Journal of Surgery, 2017
- Invasion Depth Measured in Millimeters is a Predictor of Survival in Patients with Distal Bile Duct Cancer: Decision Tree ApproachWorld Journal of Surgery, 2016
- Percutaneous biliary drainage is oncologically inferior to endoscopic drainage: a propensity score matching analysis in resectable distal cholangiocarcinomaJournal of Gastroenterology, 2015